ClinicalTrials.gg
CompletedNCT05938270ASCERTAINUpdated Jun 30, 2026

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

A Phase 1 interventional study of Saruparib (AZD5305) and Darolutamide in Prostate Cancer, sponsored by AstraZeneca. Completed at 16 sites in 6 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.

Enrollment
25th of 59
113 · median 80
Started
2023
with 8 others
Phase 1
9 of 59
2 open now
Registered
35th of 59
by date
Lead sponsor
1 of 59
AstraZeneca

Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 25th largest by enrollment, is one of 9 that started in 2023, is one of 9 in phase 1, and was the 35th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About darolutamide

darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing darolutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN).

Read the detailed description

An Open-label, Randomised, Phase-I, Multi-Centre Study to Investigate the Biological Effects of Saruparib (AZD5305) alone, Darolutamide alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN).

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate cancer, radical prostatectomy, Darolutamide, Saruparib (AZD5305)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male participants >/= 18 years old
  • participants deemed suitable for radical prostatectomy
  • participants with localised prostate cancer with unfavourable intermediate/high/very high risk eligible for prostatectomy
  • adequate organ and marrow function as per protocol
  • capable of giving signed
  • For participants participating in the Optional Genetic Research Only: Provision of signed and dated written Optional Genetic Research Information
  • Available FFPE diagnostic tumour samples
  • Participants must use a condom (with spermicide) from screening to 6 months after screening and refrain from fathering a child or donating sperm

Exclusion criteria

Exclusion Criteria:

  • As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, including, active bleeding diatheses, or active infection including HepB, and . Screening for chronic conditions is not required.

    1. Active is defined by a known positive HBsAg result. Participants with a past or resolved HBV infection (defined as the presence of HepB antibody and absence of HBsAg) are eligible.
    2. Participants positive for HCV antibody are eligible only if PCR is negative for HCV RNA.
  • Participants with any known predisposition to bleeding (eg, active peptic ulceration, recent [within 6 months] haemorrhagic stroke, proliferative diabetic retinopathy).
  • Participants with history of MDS/AML or with features suggestive of MDS/AML (as determined by prior diagnostic investigation). In case there is no Clinical MDS/AML suspicion, no specific screening for MDS/AML (by bone marrow/bone ) is required.
  • Prior within 3 years of screening whose natural history, in the Investigator's opinion, has the potential to interfere with safety and efficacy assessments of the regimen.
  • Concomitant use of drugs that are known to prolong or shorten and have a known risk of TdP.
  • Any of the following cardiac criteria:

    1. Mean resting corrected QT interval (QTcF) > 450 milliseconds or QTcF \< 340 milliseconds obtained from triplicate ECGs and averaged, recorded within 5 minutes.
    2. Any factors that increase the risk of QT prolongation, shortening or risk of arrhythmic events such as hypokalaemia, congenital long or short QT syndrome, family history of long QT syndrome, familial short QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong or shorten the QT interval.
    3. Any abnormalities in rhythm, conduction or morphology of resting eg, complete left bundle branch block, second or third degree atrioventricular block and clinically significant sinus node dysfunction not treated with pacemaker.
  • Other CVS diseases as defined by any of the following:

    1. Symptomatic heart failure (as defined by class ≥ 2).
    2. uncontrolled hypertension.
    3. hypertensive heart disease with significant left ventricular hypertrophy.
    4. History of acute coronary syndrome/acute myocardial infarction, unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention or coronary artery bypass grafting within 6 months prior to screening.
    5. cardiomyopathy of any aetiology.
    6. presence of clinically significant valvular heart disease.
    7. history of atrial or ventricular arrhythmia requiring acute treatment; participants with atrial fibrillation and optimally controlled ventricular rate (heart rate \< 100 bpm) are permitted.
    8. , or stroke within 6 months prior to screening.
    9. participants with symptomatic hypotension at screening.
  • nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of Saruparib (AZD5305).
  • History of prior malignancy, treated with chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, or other anticancer agent within 3 years of screening. Previously localised surgically treated malignancy is acceptable, if no evidence of recurrence.
  • Known allergy or to investigational product(s) or any of the of the investigational product(s).
  • Prior treatment with any systemic or localised anti-cancer treatment for the localised prostate cancer.
  • During the 4 weeks prior to the first dose, receiving immune modulatory agents including but not limited to, continuous at a dose of > 10 mg prednisone/day or equivalent.
  • Concomitant use of medications or herbal supplements known to be:

    1. Strong inducers/inhibitors (applies for Saruparib (AZD5305) and Saruparib (AZD5305) + darolutamide arms)
    2. Strong or moderate CYP3A4 and P-glycoprotein inducers (applies to darolutamide arm and Saruparib (AZD5305) + darolutamide arm) This is including, but not limited to, the prohibited medications listed in CSP Appendix G, or inability to stop the use thereof, at least 21 days or at least 5 half-lives (whichever is longer) before the first dose of study treatment until 30 days after the last dose of study treatment.
  • Treatment with any investigational agents or study interventions from a previous clinical study within 5 half-lives or 3 weeks (whichever is longer) of the first dose of study treatment.
  • Participants with to darolutamide for treatment arms
  • Unable to comply with the visits and assessments.
  • In the opinion of the Investigators should not be included in this study.

No treatment arm only: if any participant meets exclusion 4, 9 or 11, they are not to be included in the study.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Other
    Saruparib (AZD5305) only

    Participant will receive Saruparib (AZD5305) once daily for 21 days (+ up to 7 days) unless unacceptable toxicity or withdrawal of consent. Following the 21 days of study treatment, participants should undergo radical prostatectomy on Day 22 (+ up to 7 days)

    Drug: Saruparib (AZD5305)

  • Other
    Saruparib (AZD5305) + Darolutamide

    Participant will receive Saruparib (AZD5305) once daily + darolutamide twice daily for 21 days (+ up to 7 days) unless unacceptable toxicity or withdrawal of consent. Following the 21 days of study treatment, participants should undergo radical prostatectomy on Day 22 (+ up to 7 days).

    Drug: Saruparib (AZD5305) · Drug: Darolutamide

  • Other
    No Treatment

    No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice

    Other: No Treatment

  • Other
    Darolutamide Only

    Participant will receive darolutamide twice daily for 21 days (+ up to 7 days) unless unacceptable toxicity or withdrawal of consent. Following the 21 days of study treatment, participants should undergo radical prostatectomy on Day 22 (+ up to 7 days).

    Drug: Darolutamide

Interventions

  • Saruparib (AZD5305) given orally once daily

    Also known as: Darolutamide is also known as Nubeqa

  • Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg

    Also known as: Darolutamide is also known as Nubeqa

  • OtherNo Treatment

    No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice

06

What researchers measure

Primary outcomes

  1. Fold change in % γH2AX positive cells from baseline value in tumour samples

    To assess the effects of study treatment on γH2AX change in participants with localised prostate cancer

    Time frame: Tumour biopsy taken at diagnosis within approx 2 months of Day 1 planned start of study treatment; post treatment tumour biopsy taken following 21 days (+ up to 7 days) of study treatment

Secondary outcomes

  1. Severity of Treatment-Emergent AEs/SAEs per CTCAE v5.0

    To assess the safety and tolerability of study treatment in participants with localised prostate cancer

    Time frame: Day 1 to 28 days post-surgery

  2. Incidence of Treatment-Emergent AEs/SAEs per CTCAE v5.0

    To assess the safety and tolerability of study treatment in participants with localised prostate cancer

    Time frame: Day 1 to 28 days post-surgery

  3. Number of patients with abnormal laboratory values

    To assess the safety and tolerability of study treatment in participants with localised prostate cancer

    Time frame: Day 1 to 28 days post-surgery

  4. Change from baseline in blood pressure reported as clinically significant

    To assess the safety of study treatment in participants with localised prostate cancer

    Time frame: Day 1 to 28 days post-surgery

  5. Change from baseline in heart rate reported as clinically significant

    To assess the safety of study treatment in participants with localised prostate cancer

    Time frame: Day 1 to 28 days post-surgery

  6. Change from baseline in QTc value

    To assess the safety of study treatment in participants with localised prostate cancer

    Time frame: Day 1 to 28 days post-surgery

  7. Number of participants undergoing planned surgery

    To assess the impact of study treatment on surgical feasibility in participants with localised prostate cancer

    Time frame: Measured based on Day 1 to Day 21 of treatment

  8. Reasons of participants requiring treatment-related and non-treatment related delays of surgery and delays > 7 days from scheduled day

    To assess the impact of study treatment on surgical feasibility in participants with localised prostate cancer

    Time frame: Measured based on Day 1 to Day 21 of treatment

  9. Number of participants requiring treatment-related and non-treatment related delays of surgery and delays > 7 days from scheduled day

    To assess the impact of study treatment on surgical feasibility in participants with localised prostate cancer

    Time frame: Measured based on Day 1 to Day 21 of treatment

  10. Change in Ki-67 % positive cells from baseline in tumour samples

    To assess the effects of study treatment on Ki-67 change in participants with localised prostate cancer

    Time frame: Measured based on Day 1 to Day 21 of treatment

07

Study locations

16 sites
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Providence, Rhode Island 02903, United States
  • Research Site
    Melbourne, VIC 3000, Australia
  • Research Site
    South Brisbane, 4101, Australia
  • Research Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Québec, Quebec G1J 1Z4, Canada
  • Research Site
    Amsterdam, 1066CX, Netherlands
  • Research Site
    Nijmegen, 6525 GA, Netherlands
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Valencia, 46009, Spain
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Newcastle upon Tyne, NE7 7AF, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Jun 2026, 32 months.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 32 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2023
First posted
Jul 10, 2023
StartActual
Sep 21, 2023
Primary completionActual
Jun 15, 2026
CompletionActual
Jun 15, 2026
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05938270
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 10, 2023
Start date
Sep 21, 2023
Primary completion
Jun 15, 2026
Completion
Jun 15, 2026
Last update
Jun 30, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD5305 · Darolutamide

Start the discussion